A Clinical Approach to Integrative Care for OUD Recovery

Learn about the effectiveness of the clinical approach of integrative care for OUD in tackling opioid use disorders and fostering recovery.

Abstract

In this educational post, I present a comprehensive, first-person journey through the history of opioids, current epidemiology, clinical myths and stigma, diagnostic criteria, and modern treatment strategies for opioid use disorder (OUD). I integrate leading research findings and clinical guidance to explain why and how evidence-based interventions—medications for opioid use disorder (MOUD), motivational interviewing (MI), harm reduction, and functional approaches—work physiologically and clinically. I also demonstrate how integrative chiropractic care can fit into an OUD treatment plan to address musculoskeletal pain, autonomic dysregulation, and functional rehabilitation without intensifying opioid exposure. This work reflects our multidisciplinary practice at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, where Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933), serves as Medical Director and Collaborative Physician alongside me, Dr. Alexander (Alex) Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. We unify internal medicine oversight, chiropractic and rehabilitative services, personal injury care, and functional medicine to enhance safety, manage complexity, and improve patient outcomes. This post addresses clinical rationale, risk mitigation, protocols, and language best practices, with APA-7 style citations and references. It is designed for clinicians, allied professionals, patients, and families seeking clear, compassionate, and scientifically grounded guidance.

About Our Integrated Team and Care Model

• I am Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. My clinical observations and educational materials are available at:

• • healthcoach.clinic/
  • www.linkedin.com/in/dralexjimenez/

• Our practice: Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic), El Paso, Texas.
• Medical Director and Collaborative Physician: Dr. Maria Guadalupe Cardenas, MD, Board Certified in Internal Medicine (NPI #1164426749; Texas MD License #J2933), with over 40 years of experience as an internist.
• Multidisciplinary integration:

• • Medical oversight and complex condition management (Internal Medicine).
  • Integrative chiropractic care for pain modulation, neuromuscular balance, and rehabilitation.
  • Functional medicine for metabolic, inflammatory, and neuroendocrine contributors.
  • Personal injury and post-trauma rehabilitation, case coordination, and legal-medical documentation.
  • Behavioral health referrals, motivational interviewing, and care navigation.
  • MOUD, harm reduction, and preventive strategies aligned with federal and state regulations.

This integrated framework parallels best practices of modern injury and integrative clinics—ensuring medical direction by an MD while utilizing chiropractic, rehab, and functional approaches to reduce opioid-related risk and improve whole-person outcomes.

What You Will Learn

• The history and types of opioids; potency and morphine milligram equivalents (MME).
• Epidemiology: The three waves of the U.S. opioid crisis and current trend data.
• Key legislation and treatment milestones shaping clinical practice.
• Why OUD requires medical treatment; myths and stigma debunked.
• DSM-5 criteria and real-world diagnostic application.
• Language matters: person-first terms and how they change care delivery.
• Motivational interviewing: the spirit, the structure (OARS, DARN-CATS), and stages of change.
• Evidence-based therapies: methadone, buprenorphine, naloxone, naltrexone—how they work and why.
• Harm reduction: naloxone distribution, fentanyl test strips, safer-use strategies, and monitoring.
• Integrative chiropractic care’s role in multimodal OUD management, pain reprocessing, autonomic regulation, and functional rehabilitation—with medical oversight.
• Protocols, clinical pearls, and multidisciplinary workflows that improve safety and outcomes.

Setting the Stage: Why This Matters Now

We still face the consequences of decades-long shifts in opioid prescribing, illicit supply chains, and societal stressors. Research consistently shows that integrating medical and behavioral care with functional rehabilitation improves outcomes and reduces mortality in OUD. As a chiropractor and nurse practitioner trained in functional medicine, I work with Dr. Cardenas to ensure that our patients receive a fully coordinated plan tailored to biology, behavior, and environment—plus community supports. If you are a clinician, this post offers practical tools and clarity. If you are a patient or a family member, consider this an accessible roadmap for understanding options and advocating for compassionate, evidence-based care.

Opioids Overview and Clinical Classification

Types of Opioids: Natural, Semi-Synthetic, and Synthetic

Opioids are conventionally divided into three categories according to their chemical origin. Natural opioids, also termed opiates, are extracted directly from the opium poppy (*Papaver somniferum*); the principal examples are morphine and codeine. Semi-synthetic opioids are produced by chemically modifying these natural compounds; heroin (diacetylmorphine), oxycodone, and hydrocodone belong to this group. Fully synthetic opioids are manufactured entirely in the laboratory and include methadone and fentanyl.

These distinctions are clinically important. Potency, pharmacokinetic profiles, and receptor-binding characteristics vary substantially across the three classes, and those differences directly influence overdose risk, the character and severity of withdrawal, and the practical choices made in treatment planning and monitoring.

Historical Milestones

• 3400 BCE: Opium poppy cultivation in Mesopotamia (historical use as analgesic and sedative).
• 15th–16th centuries: Expanded use for pain and gastrointestinal issues (e.g., diarrhea).
• 1803: Morphine extracted, clinical analgesic innovation.
• 1832: Codeine isolated, antitussive use.
• 1874: Heroin synthesized from morphine—later found to be highly addictive.
• 1939: Methadone synthesized—clinical use in OUD maintenance begins decades later.
• 1959: Fentanyl developed—approximately 50× morphine potency; transdermal patch later introduced.
• 1966: Buprenorphine discovered—a partial agonist, later central in office-based OUD treatment.

These timelines show a modern acceleration of opioid innovation—and parallel risks—that shape today’s care strategies.

Morphine Milligram Equivalents (MME): Why Potency Indexing Is Essential

Relative potencies of commonly used opioids can be expressed in morphine milligram equivalents (MME). Tramadol is assigned approximately 0.1 MME, codeine roughly 0.15 MME, and hydrocodone about 1.0 MME, placing it on a near one-to-one footing with morphine. Oxycodone is roughly 1.5 times as potent, while hydromorphone reaches approximately 4.0 MME. Transdermal fentanyl requires particular care in conversion; under specific clinical conditions, approximately 2.4 micrograms is considered equivalent to 1 MME, yet non-linear kinetics and individual variability demand cautious interpretation.

These standardized values allow clinicians to quantify cumulative opioid exposure, compare agents of differing potencies, and more accurately estimate overdose risk. In practice, MME calculations inform prescribing limits, guide structured tapering plans, and help determine the safest timing and approach for initiating medications for opioid-use disorder.

The U.S. Opioid Crisis: Three Waves and Current Trends

Wave 1 (1999–2010): Prescription Opioids

• Sales quadrupled.
• Overdose deaths involving prescription opioids doubled (from ~2.9 to ~6.8 per 100,000).

Wave 2 (2010–2013): Heroin

• Heroin became cheaper and more accessible.
• Overdose deaths increased (from ~1.0 to ~4.9 per 100,000).
• Heroin deaths surpassed prescription opioid deaths.

Wave 3 (2013–Present): Synthetic Opioids (Fentanyl)

• Rapid proliferation of illicit fentanyl and analogs.
• Mortality skyrocketed—>1000% increases reported in many jurisdictions.
• Non-opioid sedatives (e.g., xylazine) now present in up to ~10% of fentanyl-related overdoses, compounding risk.

A federal emergency declaration in 2017 elevated OUD to a national public health priority. Current efforts combine supply-side controls, treatment expansion, and community harm reduction.

Prevalence and Misuse: What the Data Show

National survey data from the Substance Abuse and Mental Health Services Administration indicate that approximately 9.2 million people aged 12 and older have engaged in opioid misuse in recent years. Prescription pain-reliever misuse accounts for the large majority of these cases, far outnumbering heroin use by absolute count. Nevertheless, heroin and illicitly manufactured fentanyl carry a disproportionately high risk of fatal overdose because of their potency and frequent contamination.

A closer look at the figures reveals that roughly 8.1 million individuals report pain-reliever misuse alone, while approximately 0.5 million report heroin misuse without concurrent pain-reliever use and another 0.5 million report both. Total heroin misuse therefore approaches 1.1 million people.

These patterns carry clear clinical implications. Screening protocols must give equal weight to prescription-opioid risk factors and medical comorbidity while remaining alert to the elevated lethality associated with heroin and fentanyl. At the same time, access to medications for opioid-use disorder must be broadened across demographic groups. Current utilization remains highest among White males aged 35–49, a disparity that highlights ongoing equity gaps in both availability and engagement.

The economic consequences are correspondingly large. Annual costs attributable to the opioid crisis are estimated to exceed 193 billion dollars when health-care utilization, lost productivity, criminal-justice involvement, and broader societal impacts are taken into account.

Policy Milestones and Their Clinical Impact

• Harrison Narcotics Tax Act (1914): Criminalized non-medical opiate use.
• Controlled Substances Act (1970): Established DEA scheduling; reshaped prescribing oversight.
• Narcotic Addiction Treatment Act (1974): Federal regulation of methadone programs.
• Drug Addiction Treatment Act (DATA 2000): Office-based buprenorphine prescribing with waiver.
• Comprehensive Addiction and Recovery Act (2016): Expanded MOUD prescribing to NPs/PAs.
• SUPPORT Act (2018): Expanded OUD treatment through Medicare/Medicaid reforms.
• Mainstreaming Addiction Treatment (MAT) Act (2023): Eliminated the buprenorphine waiver; DEA-registered clinicians can prescribe Schedule III buprenorphine consistent with license authority.

These changes aim to normalize OUD treatment alongside other chronic conditions—countering structural stigma and broadening access.

Why We Treat OUD Medically: Debunking Myths and Addressing Stigma

Common Myths and Evidence-Based Rebuttals

• Myth: “MOUD replaces one addiction with another.”

• • Reality: MOUD treats a chronic brain condition by stabilizing receptor activity, reducing cravings, and dramatically lowering mortality; akin to insulin for diabetes or antihypertensives for hypertension (Volkow et al., 2014).

• Myth: “Recovery without medication is superior.”

• • Reality: Comparative effectiveness studies show MOUD reduces mortality by up to ~60% and lowers illicit use and overdose risk (Sordo et al., 2017).

• Myth: “OUD medications are not effective.”

• • Reality: Robust evidence supports methadone, buprenorphine, and naltrexone in reducing morbidity and mortality, with buprenorphine offering safety advantages (Chu et al., 2008; Sordo et al., 2017).

• Myth: “MOUD is for people who are weak.”

• • Reality: OUD reflects neuroadaptations in reward, stress, and executive circuits; MOUD addresses neurobiology and restores function (Koob & Volkow, 2016).

Stigma Types and Consequences

Stigma operates at multiple levels and remains one of the most persistent barriers to effective care for opioid-use disorder. Public stigma continues to rest on the misconception that the condition is primarily a matter of criminality rather than a chronic medical illness, often generating opposition to policies that expand treatment access. Structural stigma is embedded in the historical criminalization of drug use, in regulatory frameworks that once created unnecessary barriers to prescribing, and in chronic underfunding of evidence-based services. Provider bias appears in moralizing attitudes, exaggerated legal fears, and measurable differences between rural and urban clinical environments. Internalized stigma takes the form of profound personal shame and the still-common narrative, sometimes reinforced within peer communities, that recovery achieved with the help of medication is somehow incomplete or inauthentic.

The clinical consequences are substantial: lower rates of medication uptake, delayed entry into care, and ultimately poorer health outcomes.

Language itself functions as a practical and powerful intervention. Person-first phrasing—”person with opioid-use disorder,” “person in recovery,” or “people who use drugs”—centers the individual rather than the diagnosis. Laboratory results are more accurately and neutrally described as “positive” or “negative” for a given substance rather than “dirty” or “clean.” In neonatal contexts, the term “neonatal opioid withdrawal” (or neonatal opioid withdrawal syndrome) replaces the inaccurate and stigmatizing label “addicted baby.” The word “misuse” is preferred over “abuse.” These deliberate shifts reduce bias, strengthen trust between patients and clinicians, and support greater adherence to treatment.

Diagnosing OUD: DSM-5 Criteria and Clinical Reasoning

Opioid-use disorder is diagnosed when at least two of the eleven DSM-5 criteria are met within twelve months. These criteria capture patterns of problematic use and its consequences, not quantity alone. They include taking opioids in larger amounts or for longer periods than intended; persistent desire or unsuccessful efforts to cut down or control use; spending a great deal of time obtaining, using, or recovering from the effects of opioids; craving or a strong urge to use; recurrent use that fails to fulfill major role obligations at work, school, or home; continued use despite persistent or recurrent social or interpersonal problems; reduction or abandonment of important social, occupational, or recreational activities; recurrent use in physically hazardous situations; and continued use despite knowledge of persistent physical or psychological problems likely caused or exacerbated by opioids. The final two criteria address tolerance (the need for markedly increased amounts to achieve the desired effect or a markedly diminished effect with continued use of the same amount) and withdrawal (the characteristic withdrawal syndrome or the use of opioids to relieve or avoid withdrawal symptoms).

An important diagnostic clarification is that tolerance and withdrawal alone are insufficient for the diagnosis when opioids are taken solely under appropriate medical supervision. At least one of the first nine behavioral or functional criteria must also be present.

Severity is graded according to the number of criteria met: mild when two or three are present, moderate when four or five are present, and severe when six or more are present.

In clinical practice, it is most useful to focus on functional impact and patterns of behavior change rather than on absolute quantity of use. The behavioral criteria more accurately reflect disorder severity and therefore better guide the intensity and type of treatment required.

Case Study: Rewriting with Compassionate Language

Clinical documentation has historically relied on language that carries unintended judgment. Phrases such as abusing heroin IV,” references to an “addict community,” descriptions of a newborn as “born addicted,” or the use of “clean” to indicate periods of abstinence all embed moral evaluation into what should be objective clinical records.

A more precise and compassionate approach replaces these terms with neutral, person-centered descriptions. For example, “The patient reports misusing heroin intravenously from ages 20 to 30” accurately conveys the history without pejorative verbs. “She began daily use after trying heroin at age 20” states the timeline. “Her last use of heroin was one month ago, after seven years without use” provides clear temporal information while avoiding the value-laden label “clean.” “She entered recovery after a non-fatal overdose and initiated medications for opioid-use disorder” focuses on the sequence of clinical events. Protective factors can be noted as “a supportive family and regular involvement with a recovery community.” In neonatal contexts, “Her daughter experienced neonatal opioid withdrawal and is healthy now” correctly identifies the physiologic condition and updates the current status.

These linguistic adjustments render documentation more objective and nonjudgmental. Equally important, they strengthen the therapeutic alliance by signaling respect and reducing the shame that often accompanies encounters with the healthcare system.

Motivational Interviewing (MI): Putting Patients in the Driver’s Seat

The Spirit of MI

• Partnership: Collaborate rather than persuade.
• Evocation: Elicit the patient’s own motivations and values.
• Acceptance: Respect autonomy, affirm strengths, maintain empathy.
• Compassion: Be nonjudgmental and free from blame/shame.

The MI Process

• Engaging: Build rapport and trust.
• Focusing: Identify a shared, patient-centered goal.
• Evoking: Draw out reasons for change.
• Planning: Co-create specific, actionable steps.

Practical Tools

• OARS:

• • Open-ended questions: “Can you tell me about your recovery journey?”
  • Affirmations: Reinforce strengths and positive steps.
  • Reflections: Emphasize understanding; use more reflections than questions.
  • Summaries: Validate and clarify shared understanding.

• DARN-CATS:

• • Desire: “What do you hope our work accomplishes?”
  • Ability: “What might you be able to change about opioid use?”
  • Reasons: “Why do you want to cut back or stop?”
  • Need: “What do you need to feel ready?”
  • Commitment: “I want to…”
  • Activation: “I am ready to…”
  • Taking steps: “I have started…”

Stages of Change: Recognize and Respond

• Precontemplation: “I don’t think my drug use is impacting my life.”
• Contemplation: “I think my marriage will improve if I reduce my drug use.”
• Preparation: “I looked up an NA meeting near my house.”
• Action: “I reduced the number of days I use.”
• Maintenance: “I’ve been on MOUD for a year.”

Tailor interventions to the stage. For precontemplation, explore ambivalence; for preparation, assist planning; for maintenance, support relapse prevention.

Enhancing Health Together: Embracing Multidisciplinary Evaluation and Treatment- Video

Non-Pharmacological Supports: Building a Strong Recovery Ecosystem

Individual behavioral therapy remains a core non-pharmacological support and can be delivered by psychologists, social workers, or trained recovery coaches. These services are increasingly available through sliding-scale or community-based options that improve access for uninsured patients, and peer recovery coaches can be especially valuable because of their lived experience.

Group-based supports expand the continuum of care. SMART Recovery offers a structured, skills-focused approach grounded in cognitive-behavioral and rational-emotive principles. Traditional twelve-step fellowships such as Alcoholics Anonymous and Narcotics Anonymous remain widely accessible and include both religiously oriented and more secular variants so that individuals can select a group aligned with their personal beliefs. Secular Organizations for Sobriety provides an explicitly non-religious alternative for those who prefer that framework.

An essential clinical principle is that participation in any group should never be made a prerequisite for receiving medications for opioid-use disorder. Medical treatment stands independently; group involvement is offered as a complementary resource rather than a gatekeeping requirement. Where local regulations and meeting policies permit, clinicians are encouraged to observe open meetings so they can speak from direct experience when recommending community resources to patients.

Pharmacological Management: How MOUD and Antagonists Work and Why

Opioid Receptor Dynamics and Respiratory Depression Risk

Opioids interact with the mu-opioid receptor in three principal ways, and these differences shape both therapeutic effect and clinical risk. Full agonists such as morphine, heroin, methadone, and fentanyl fully activate the receptor. As dose increases, so does the degree of respiratory depression, which is the primary mechanism underlying fatal overdose.

Partial agonists, with buprenorphine as the leading example, activate the same receptor only partially. This limited activation produces a ceiling effect on respiratory depression while still effectively suppressing craving and withdrawal symptoms, thereby offering a wider margin of safety.

Antagonists occupy the receptor without activating it. Naloxone rapidly displaces agonists and reverses overdose; naltrexone provides sustained blockade that prevents opioids from producing euphoria and also attenuates the rewarding effects of alcohol.

These distinctions rest on the physiology of the mu receptor itself. Activation of the receptor modulates analgesia, reward pathways, and brainstem circuits that control respiration. Partial agonism therefore stabilizes receptor function sufficiently to relieve withdrawal and craving without driving the high-risk respiratory suppression characteristic of full agonists.

Methadone

Methadone is a full mu-opioid agonist classified as a Schedule II controlled substance and is dispensed exclusively through certified opioid treatment programs. Common side effects include constipation, dizziness, sedation, nausea, and sweating. More serious risks involve prolongation of the QTc interval—particularly at daily doses above 100 mg—and respiratory depression. Absolute contraindications include known allergy, acute or severe asthma, and gastrointestinal obstruction. Despite these considerations, methadone demonstrates high efficacy for treatment retention and overdose reduction. It is especially well suited to individuals who require the structure of daily observed dosing or who present with high opioid tolerance.

Buprenorphine

Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa receptor; it is classified as a Schedule III controlled substance. Because of its high receptor affinity, it can displace full agonists and therefore may precipitate withdrawal if induction begins too early. Its partial agonism produces a clinically useful ceiling effect that limits respiratory depression while still effectively reducing craving and withdrawal symptoms.

Common side effects include headache, constipation, nausea, orthostatic hypotension, and, with sublingual formulations, oral hypoesthesia. Serious risks are uncommon but include respiratory depression—particularly when buprenorphine is combined with benzodiazepines—and rare instances of hepatotoxicity. Contraindications include known allergy and severe hepatic impairment; use combination products containing naloxone with caution.

Clinically important drug interactions must be considered. Concurrent use of benzodiazepines increases respiratory-depression risk, yet the FDA advises that the benefits of continuing buprenorphine often outweigh this risk and that the medication should not be withheld from indicated patients. CYP3A4 inhibitors such as erythromycin or grapefruit juice can raise buprenorphine concentrations, while CYP3A4 inducers such as rifampin or St. John’s wort can lower them. Serotonergic agents require monitoring for serotonergic effects, although the therapeutic benefits of buprenorphine again frequently outweigh the risks.

Taken together, these pharmacologic properties make buprenorphine especially well suited to office-based treatment. Its favorable safety profile and demonstrated effectiveness in reducing mortality have established it as a cornerstone of contemporary opioid-use-disorder care.

Naloxone

Naloxone is a pure opioid antagonist and remains one of the most effective tools for reversing life-threatening overdose. Its relatively short half-life compared with many opioids—especially fentanyl and long-acting agents—creates a risk of re-narcotization once the antagonist wears off; therefore, every administration must be followed by immediate activation of emergency medical services.

Practical education focuses on both available formulations and correct technique. The most widely distributed product is intranasal NARCAN, which delivers 4 mg in 0.1 mL; one device constitutes a single dose, and if there is no response within two minutes,s a second device is administered in the opposite nostril. Injectable formulations are still used primarily by emergency medical personnel. Training of family members and close contacts is essential, and naloxone should be co-prescribed whenever a patient is using opioids or is at risk of encountering contaminated non-opioid drugs.

When opioids are present, naloxone precipitates acute withdrawal; in the absence of opioids, it produces minimal adverse effects. The clinical rationale for widespread distribution and training is straightforward: ready access to naloxone measurably reduces the number of fatal overdoses.

Naltrexone

Naltrexone is a mu- and kappa-opioid receptor antagonist used in the treatment of both opioid-use disorder and alcohol-use disorder. By occupying the receptor, it blocks the rewarding effects of opioids and simultaneously reduces alcohol-induced dopamine release, thereby lowering craving and decreasing the number of heavy-drinking days.

Two formulations are available. The extended-release injectable preparation (Vivitrol) delivers 380 mg intramuscularly into the gluteal muscle once monthly. Patients must be opioid-free for at least seven days before the first injection; the product requires refrigeration between 36 °F and 46 °F, and a minimum twenty-one-day interval is observed for individuals who metabolize the drug rapidly. An oral tablet is typically dosed at 50 mg daily.

Common side effects include headache, anorexia, diarrhea, nausea, and, with the injectable form, injection-site reactions. More serious risks encompass hepatitis, eosinophilic pneumonia, and the potential for depression or suicidality. Naltrexone is contraindicated in the presence of acute hepatitis or liver failure and in any situation that may require opioids, such as anticipated surgery.

Clinically, naltrexone is most appropriate for patients who can maintain an opioid-free status and is especially valuable when alcohol-use disorder co-occurs.

Harm Reduction: Practical Steps that Save Lives

• Naloxone distribution and training for families and friends.
• Fentanyl test strips: Encourage testing of drug supply (including stimulants like cocaine that may be contaminated).
• Never Use Alone hotline: Provide an address and maintain contact; call emergency services if unresponsive.
• Clean needle exchange: Reduce HIV, hepatitis C, and other bloodborne pathogens.
• Urine drug screens: Educate patients nonjudgmentally about unexpected positives (e.g., fentanyl-laced heroin).
• Prescription Monitoring Programs (PMPs): Coordinate prescribing; reduce duplicative or unsafe regimens.
• Motivational interviewing: Maintain patient-centered goals; reduce confrontation; promote adherence.

Rationale:

• Harm reduction recognizes the reality of use patterns and provides immediate protections against fatal outcomes—without requiring abstinence to deliver care.

Integrative Chiropractic Care in OUD Treatment: Where It Fits and Why It Matters

As a chiropractor and nurse practitioner within a medical-directed clinic, I integrate chiropractic interventions to address pain, function, and autonomic balance—key drivers of opioid reliance and relapse risk.

Clinical Rationale

• Pain modulation:

• • Spinal and peripheral joint dysfunction contributes to nociceptive input and central sensitization.
  • Evidence-based manual therapies can reduce pain intensity, improve mobility, and lower reliance on high-MME opioids (Qaseem et al., 2017; Enthoven et al., 2016).

• Autonomic regulation:

• • Cervical and thoracic manipulation/mobilization and soft-tissue techniques influence sympathetic-parasympathetic balance via spinal intersegmental mechanics and afferent modulation.
  • Improved sleep and stress tolerance reduce OUD relapse triggers (Koob & Volkow, 2016).

• Functional rehabilitation:

• • Corrective exercises, neuromuscular re-education, and graded exposure decrease pain-related fear and movement avoidance—common after injuries and during withdrawal or early MOUD stabilization.

• Inflammation and metabolic contributors:

• • Functional medicine approaches address systemic inflammation (e.g., CRP, IL-6), insulin resistance, and micronutrient deficits—biological factors that amplify pain and mood symptoms.

• Safety with MOUD:

• • Chiropractic care avoids increasing opioid load and can complement buprenorphine/methadone by improving function and mood—supporting adherence and lowering overdose risk.

Specific Integrative Methods

• Manual therapies:

• • High-velocity, low-amplitude (HVLA) manipulation when indicated and safe.
  • Mobilization and instrument-assisted soft tissue therapies.
  • Myofascial release, trigger point techniques, and proprioceptive neuromuscular facilitation (PNF).

• Corrective exercise:

• • McGill core stabilization, DNS principles, multi-planar hip hinge retraining, shoulder scapular stabilization, and lumbopelvic coordination.

• Pain neuroscience education:

• • Reframe pain as a protective output modulated by context, threat, and expectation to reduce catastrophizing and reliance on passive treatments.

• Graded exposure:

• • Progressive return to feared movements; integrate resilience and breath practices.

• Autonomic balancing:

• • Diaphragmatic breathing, Heart Rate Variability biofeedback where available, and cervical and thoracic mobility to reduce stress-mediated headaches and upper-body tension.

• Functional medicine:

• • Nutritional interventions (anti-inflammatory dietary patterns, omega-3 fatty acids, magnesium for sleep and muscle function).
  • Gut health support where indicated; sleep hygiene protocols.
  • Laboratory assessments guided by Internal Medicine oversight for safety (e.g., liver enzymes, electrolytes, HbA1c, lipids).

Why Patients Benefit

• Reduced pain intensity and improved quality of life.
• Lower risk of escalating opioid dose.
• Better engagement with MOUD and behavioral interventions.
• Improved sleep, mood, and energy—all protective against relapse.

Medical Oversight: The Role of Dr. Maria Guadalupe Cardenas, MD

In our clinic, Dr. Cardenas provides medical direction and collaborative oversight essential for safe, comprehensive OUD management:

• Diagnostics:

• • Full medical evaluation: cardiopulmonary status, hepatic function, psychiatric comorbidities.
  • Laboratory and imaging guidance where appropriate.

• MOUD management:

• • Buprenorphine induction protocols; methadone coordination with OTPs; naltrexone candidacy evaluation.
  • Monitoring for drug interactions, liver function, QTc issues.

• Complex care:

• • Management of co-occurring conditions (e.g., diabetes, hypertension, liver disease).
  • Coordination with surgeons for perioperative pain planning (especially with naltrexone or MOUD).

• Risk mitigation:

• • Naloxone co-prescribing; PMP monitoring; benzodiazepine risk assessment; sedation safety.

• Interdisciplinary orchestration:

• • Align chiropractic care and functional interventions with medical priorities.
  • Behavioral health referrals; social supports; case management for personal injury or legal considerations.

Her 40+ years of internal medicine experience ensure our patients receive safe, coordinated care that is evidence-based and responsive to real-world complexities.

Personal Injury and Post-Trauma Rehabilitation: Integrative Pathways to Recovery

For patients with injury-related pain and functional deficits, our integrated model prioritizes:

• Immediate safety and acute pain control without escalating opioid risk.
• Early mobilization and joint stability work to prevent chronic pain and central sensitization.
• Documentation for legal-medical processes; coordinated communication with attorneys and adjusters.
• Functional assessment (movement pattern analysis, ROM, strength/endurance metrics).
• Gradual return-to-work and activity plans tailored to physical and psychosocial readiness.
• MI for adherence; harm reduction education; OUD screening to catch iatrogenic risks early.

Clinical Protocols: Putting It All Together

Intake and Assessment

• Medical: Comprehensive history, physical exam, labs (including LFTs), EKG if methadone is considered.
• OUD screening: DSM-5 criteria; validated tools (e.g., ASSIST, DAST-10).
• Pain/function: ROM, pain scales, functional capacity, movement analysis.
• Behavioral health: Depression/anxiety screening (PHQ-9/GAD-7), trauma history, social supports.
• Risk stratification: Overdose risk, polysubstance use, benzodiazepines, sleep apnea.

Treatment Planning

• MOUD selection:

• • Buprenorphine for outpatient office-based stabilization; consider methadone for high tolerance or structured daily monitoring; naltrexone for opioid-free candidates motivated for antagonist therapy (with AUD benefit).

• Chiropractic and rehab:

• • Tailor manual therapy and corrective exercise to pain generators and functional goals; use graded exposure and pacing.

• Functional medicine:

• • Anti-inflammatory nutrition, sleep hygiene, targeted supplements with medical clearance.

• Harm reduction:

• • Naloxone distribution and training; fentanyl strips; Never Use Alone hotline; needle exchange; PMP monitoring.

• MI and behavioral supports:

• • OARS and DARN-CATS structure; stage-matched interventions; referral to CBT or trauma-informed care when indicated.

Monitoring and Safety

• Visit cadence:

• • Early phase: Weekly to biweekly; fill MOUD prescriptions with appropriate follow-up.

• Labs and vitals:

• • LFTs for naltrexone; QTc for methadone; monitor benzodiazepine co-use risk.

• Outcomes tracking:

• • Pain intensity, sleep, function, cravings, adherence; relapse prevention planning.

• Coordination:

• • Regular case reviews with Dr. Cardenas; updates to legal-medical documentation; communication with external providers.

How the Physiology Supports Our Approach

Opioid-use disorder is a multi-system disorder whose neurobiology helps explain why an integrated treatment approach is effective. Chronic opioid exposure profoundly alters reward circuitry. Repeated stimulation of the mesolimbic dopamine pathway—from the ventral tegmental area to the nucleus accumbens—diminishes sensitivity to natural rewards while amplifying reactivity to drug-related cues, thereby reinforcing compulsive seeking.

Concurrently, stress systems become hyper-responsive. Heightened corticotropin-releasing factor signaling intensifies the negative affective state of withdrawal and drives continued use as a means of relief (Koob & Volkow, 2016). Executive function is also compromised: impaired prefrontal regulation weakens self-control and decision-making. Motivational interviewing helps restore these capacities by emphasizing autonomy and values-based planning, thereby re-engaging higher-order cognitive systems.

Pain processing is likewise disrupted. Descending inhibitory pathways that run from the periaqueductal gray to the rostral ventromedial medulla can be strengthened through non-pharmacologic therapies; purposeful movement further calibrates nociceptive input and reduces central sensitization. Autonomic balance improves when parasympathetic tone is enhanced through breathing practices and mobility work, mitigating anxiety, improving sleep, and lessening stress-linked craving. Finally, systemic inflammation contributes to both pain and depressive symptoms; elevated pro-inflammatory cytokines can be lowered through targeted dietary and lifestyle adjustments that enhance mood resilience.

Within this framework, medications for opioid-use disorder stabilize receptor activity, integrative rehabilitation recalibrates pain pathways and physical function, and motivational interviewing engages values-driven behavior change. Together, these modalities address the disorder’s multi-system nature.

Clinical Observations from Practice

From my experience:

• Patients stabilizing on buprenorphine often report improved sleep and reduced hyperalgesia within weeks—creating an opportunity to intensify movement and corrective exercise without triggering pain flares.
• Autonomic-focused chiropractic care (cervicothoracic mobility, soft-tissue release) lowers headache frequency and muscle tension—particularly in patients with stress-driven exacerbations.
• Graded exposure strategies reduce fear-avoidance patterns, enabling incremental functional gains that patients find empowering; this sustains MOUD adherence by improving quality of life.
• Nutrition and sleep interventions amplify these gains; magnesium glycinate, omega-3s, and consistent sleep routines can support mood and reduce pain perception (with medical clearance).
• Compassionate language dramatically improves engagement; patients who feel respected are more likely to disclose, adhere, and co-create effective plans.

These observations align with our clinic’s integration of chiropractic, MOUD, functional medicine, and medical oversight—anchored by Dr. Cardenas’s internal medicine leadership.

Practical Tips for Clinicians and Care Teams

• Normalize MOUD: Frame it as standard medical therapy for a chronic condition.
• Use person-first language: It shifts mindset and improves rapport.
• Safety first: Naloxone for all at risk; teach families; use fentanyl test strips.
• Avoid coercion: Do not make MOUD contingent on group attendance; separate medical and behavioral choices.
• Coordinate care: PMPs, case discussions, cross-disciplinary communication.
• Tailor exercise: Start low, go slow; prioritize form and function; avoid flare-ups.
• Monitor interactions: Benzodiazepines, CYP3A4 modulators, serotonergic agents; adjust with medical oversight.
• Address sleep and nutrition: Foundational supports reduce relapse risk.
• Plan for surgery: Naltrexone requires downtime for opioid analgesia; coordinate carefully.
• Document compassionately: It matters for patient trust—and for medicolegal transparency.

How Patients and Families Can Engage

• Ask about MOUD options: Buprenorphine, methadone (via OTP), naltrexone—understand benefits and requirements.
• Request naloxone: Keep it accessible; train family and friends.
• Consider integrative care: Chiropractic and rehabilitation can reduce pain and help you move more confidently.
• Explore groups if helpful: SMART, NA, secular options—choose what fits your values.
• Use safer-use strategies: Fentanyl test strips, Never Use Alone hotline, clean needle exchanges.
• Communicate openly: Share all substances, supplements, and stressors; we’re here to help, not judge.
• Build routines: Sleep, nutrition, movement, and goal tracking support stability.

Conclusion

Opioid-use disorder is a complex, chronic medical condition that requires more than any single intervention. The most effective care integrates evidence-based medications, compassionate and nonjudgmental communication, practical harm-reduction strategies, and integrative rehabilitation—all delivered under continuous medical oversight. In our clinic, Dr. Maria Guadalupe Cardenas, MD, provides that medical direction, ensuring clinical safety, regulatory alignment, and a coordinated treatment framework. Concurrently, integrative chiropractic and functional-medicine strategies help patients restore physical function, reduce pain drivers, and rebuild physiological resilience. When biology, behavior, and environment are addressed together, measurable outcomes improve, and individuals can reclaim their lives with dignity.

References

• Koob, G. F., & Volkow, N. D. (2016). Neurobiology of addiction: a neurocircuitry analysis. The Lancet Psychiatry, 3(8), 760–773.
• Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ, 357, j1550.
• Volkow, N. D., Frieden, T. R., Hyde, P. S., & Cha, S. S. (2014). Medication-assisted therapies—tackling the opioid-overdose epidemic. NEJM, 370(22), 2063–2066.
• Chu, L. F., Clark, D. J., & Angst, M. S. (2008). Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: A randomized controlled trial. Pain, 140(3), 158–167.
• Qaseem, A., Wilt, T. J., McLean, R. M., & Forciea, M. A. (2017). Noninvasive treatments for acute, subacute, and chronic low back pain: A clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 166(7), 514–530.
• Enthoven, W. T. M., Roelofs, P. D. D. M., Deyo, R. A., et al. (2016). Non-steroidal anti-inflammatory drugs for chronic low back pain. Cochrane Database of Systematic Reviews, (2), CD012087.

SEO tags: opioid use disorder, MOUD, buprenorphine, methadone, naltrexone, naloxone, harm reduction, motivational interviewing, integrative chiropractic care, internal medicine oversight, functional medicine, personal injury rehabilitation, El Paso clinic, Dr. Alexander Jimenez, Dr. Maria Guadalupe Cardenas, opioid crisis, MME, DSM-5, stigma reduction, language in healthcare